A slowly progressing neurological syndrome that combines action sensitive and stimulus-sensitive myoclonus with cherry-red spots at the macula in patients with a-neuraminidase deficiency has been described recently.'-3 In these patients, there were no dementia or bone deformities, and generalised seizures that occurred in two patients were easily controlled by antiepileptic therapy. According to Rapin et a12 this peculiar syndrome should be kept distinct from other more malignant storage disorders and progressive myoclonic epilepsies and put in a new class of diseases characterised by accumulation of sialidated glycopeptides and glycolipids in tissues, owing to a deficiency of neuraminidase. Lowden and O'Brien4 have defined as Sialidosis type I the Cherry-red Spot Myoclonus Syndrome (CRS-MS) with normal intelligence and a-neuraminidase deficiency.
A slowly progressing neurological syndrome that combines action sensitive and stimulus-sensitive myoclonus with cherry-red spots at the macula in patients with a-neuraminidase deficiency has been described recently.'-3 In these patients, there were no dementia or bone deformities, and generalised seizures that occurred in two patients were easily controlled by antiepileptic therapy. According to Rapin et a12 this peculiar syndrome should be kept distinct from other more malignant storage disorders and progressive myoclonic epilepsies and put in a new class of diseases characterised by accumulation of sialidated glycopeptides and glycolipids in tissues, owing to a deficiency of neuraminidase. Lowden and O'Brien4 have defined as Sialidosis type I the Cherry-red Spot Myoclonus Syndrome (CRS-MS) with normal intelligence and a-neuraminidase deficiency.
The present report deals with electrophysiological, pharmacological and biochemical findings in a case of CRS-MS observed recently. 
Case report
The patient was an Italian male aged 21 years. There was nothing significant in the family history. The patient was cyanotic at birth but his psychomotor development 'had been normal. At age 13 years he had an episode of acute polyarthritis diagnosed as rheumatic fever. At age 18 years the patient began to complain of walking clumsily and a few months later he had a short tonic-clonic generalised seizure. Neurological examination performed at that time showed mild dysmetria and brisk tendon reflexes.
In the following months his difficulties in standing and walking rapidly became worse with the appearance of muscular jerks that affected all four limbs and were exacerbated by voluntary movement. A progressive irregular course eventually led to a condition in which the patient was no longer able to care for himself. When he was admitted to hospital in December 1978 (at the age of 21 years) neurological examination showed diffuse hypotonia, brisk deep reflexes and bilateral Babinski signs. A mild ataxia was evident on finger-nose and heel-knee tests, although evaluation was made difficult by the superimposed myoclonic jerks. The myoclonic jerks were absent at rest but precipitated by any attempt to change posture or even by a simple request to move. The focal character of the myoclonus was evident only at the beginning of the voluntary movement owing to its marked tendency to spread rapidly and end up in repeated massive bilateral 934 jerks. In addition to the action and intention myoclonus, there was also reflex myoclonus that could be triggered by passive movements and tactile stimulation. Examination of the ocular funidus showed a normal optic disk and a cherry-red spot in the macular region, more striking in the right eye (fig 1) . The results of audiometric examination were normal. The patient was still able to communicate satisfactorily with other people, talking very slowly and using limited mimic movements. He showed no sign of mental impairment.
The CT scan was normal. Blood examination (red and white cell count, erythrocyte sedimentation rate, electrolytes, nitrogen, glucose and bilirubin levels, SGOT, SGPT, alkaline phosphatase, serum protein electrophoresis, serum immunodiffusion) was normal. In the cerebrospinal fluid cell count, total protein, glucose, chloride, and protein electrophoresis and immunodiffusion were normal; 5-hydroxyindoleacetic acid level was 35 57 ng/ml (controls mean value 31-37+4-43). Blood and urinary aminoacids were normal. Assays of arylsulphatase A and ,J-galactosidase in the leucocyte also were normal. A chronic trial was then started with increasing oral doses of L-5HTP plus carbidopa, up to 600 and 125 mg respectively. These two drugs were simply added to the preceding therapy, which was maintained unchanged. During 12 months of follow-up, the beneficial effects of L-5HTP on action-sensitive and stimulus-sensitive myoclonus were confirmed. The ensuing improvement in motor performance increased the degree of self-sufficiency of the patient in some daily activities such as dressing, washing and eating. So far there has been no sign of loss of efficacy. Neither clinical nor laboratory side effects have been observed. Biochemical findings Fibroblasts from normal controls, a patient with mucolipidosis III (ML III) and the CRS-MS patient were grown in Eagle's MEM, supplemented with 10% foetal calf serum as previously described.6 Cells were analysed for lysosomal enzymes and a-neuraminindase activities after five to 15 subcultures, seven days after they became confluent.
Lysosomal enzymes in cultured cells and in culture medium were analysed as follows: (a) cells were washed twice with tris-buffered saline (TBS), pH and trypsinised with 025% trypsin-l 0 mM EDTA, Neuraminidase activity in sonicated fibroblasts was determined under optimal conditions with a-Nacetyl-neuraminylactose (a2-3) as substrate as recently described.8 Table 1 shows the activities of a-neuraminidase in the cells of controls, of the ML III patient and of the CRS-MS patient: a-neuraminidase was markedly reduced, to about 5 % of the mean control values in the cells of the two patients. Table 2 shows the activities of five lysosomal hydrolases in cultured fibroblasts and in the culture media from the controls and the two patients. A marked reduction of the activity of the five hydrolases was observed in the cells of the ML III patient, with corresponding increases in enzyme activity in his culture medium, except for that of 13-galactosidase; this latter enzyme and the other four hydrolases measured in the cells and in the culture medium of CRS-MS patient showed activities comparable to those of controls. Neuraminidase deficiency has been regarded as a primary defect in this condition and the disease named "Sialidosis."20 21 The spectrum of a-neuram.inidase deficiency was broadened by the reports of Rapin et a!2
and O'Brien,' when they described their three patients with progressive incapacitating myoclonus, macular cherry-red spots and a-neuraminidase deficiency in their cultured cells. These patients differed from those with ML I in the adult onset of the signs and symptoms, the lack of bone dysplasia and the normal intelligence. They share with the ML I patient macular cherry-red spots, myoclonus and a-neuraminidase deficiency.2 Moreover, additional patients with clinical features distinct from those of the patients with mucolipidoses I, II, III and the cherry-red spot myoclonus syndrome, but with a-neuraminidase deficiency, have been reported: an eight-month-old girl with normal mental development and dysostosis multiplex'0 and an adult patient with skeletal dysplasia, cerebellar ataxia, cherry-red spot and myoclonus22: conversely, patients with a phenotypic condition similar to mucolipidosis I and to the CRS-MS have been described in whom the biochemical de- The degree of a-neuraminidase deficiency in cultured cells from our patient, as measured with a-2-3 neuraminylactose, was not distinguishable from that found in cultured cells of a patient with ML III (table 2). The two patients could not be distinguished on the basis of a-neuraminidase activity in their cultured cells. However, the two diseases are clinically and biochemically different; cultured cells from the CRS-MS patient showed both intracellular and extracellular activities of lysosomal enzymes comparable to those of controls, while cells from ML III patient showed the known"8 decrease in intracellular and increase in extracellular lysosomal enzyme activities (table 2) .
a-neuraminidase deficiency is a secondary defect in I-cell disease,23 29 but it is considered a primary defect in both mucolipidosis I and the cherry-red spot myoclonus syndrome. We believe, however, that a more detailed characterisation of a-neuraminidase activity using natural substrates8 is needed in order to link well-defined clinical conditions with biochemical abnormalities. 
